Loss of Bcl-x in Ph B-ALL increases cellular proliferation and does not inhibit leukemogenesis

The kinase inhibitors imatinib mesylate and dasatinib are the preferred treatment for Philadelphia chromosome–positive (Ph ) leukemias, and they are highly successful in the chronic phase of chronic myeloid leukemia (CML). However, they are not efficient in Ph B-cell acute lymphoblastic leukemia (B-ALL). Ph leukemia cells are highly resistant to apoptosis, and evidence from cell lines and primary cells suggest Bcl-xL as a critical mediator of resistance to apoptosis: however, this concept has never been rigorously tested in an animal model. To clarify the role of Bcl-xL in Ph B-ALL, we generated 2 mouse models. In the first model, Ph B-ALL and loss of Bcl-xL expression are coinduced; in the second model, leukemia is induced with expression of Bcl-xL protein well above the levels found in wild-type lymphoblasts. Deletion of Bcl-xL did not inhibit leukemogenesis or affect apoptosis, but increased cellular proliferation. Consistent with this result, overexpression of Bcl-xL led to decreased cellular proliferation. These models reveal an unexpected role for Bcl-xL in cell-cycle entry and the proliferation of tumor cells. (Blood. 2008;111:3760-3769)

[1]  B. Druker,et al.  Chronic Myeloid Leukemia , 2007, Methods in Molecular Biology.

[2]  J. Radich,et al.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.

[3]  Michael G. Kharas,et al.  KLF4 suppresses transformation of pre-B cells by ABL oncogenes. , 2007, Blood.

[4]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[5]  S. Kaufmann.  Imatinib spells BAD news for Bcr/abl-positive leukemias , 2006, Proceedings of the National Academy of Sciences.

[6]  L. Hennighausen,et al.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. , 2006, Blood.

[7]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[8]  J. Ihle,et al.  Regulation of interleukin 7–dependent immunoglobulin heavy-chain variable gene rearrangements by transcription factor STAT5 , 2005, Nature Immunology.

[9]  S. Derdak,et al.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.

[10]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[11]  K. Akashi,et al.  Transgenic targeting with regulatory elements of the human CD34 gene. , 2002, Blood.

[12]  Matthew B. Wilson,et al.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.

[13]  M. Wasik,et al.  Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. , 2002, Blood.

[14]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[15]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[16]  E. Lam,et al.  BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression* , 2001, The Journal of Biological Chemistry.

[17]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[18]  L. Hennighausen,et al.  Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. , 2000, Development.

[19]  S. McKenna,et al.  Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. , 2000, The oncologist.

[20]  M. Hallek,et al.  Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. , 2000, Blood.

[21]  L. Hennighausen,et al.  Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. , 2000, Molecular endocrinology.

[22]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[23]  R. Laucirica,et al.  Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model , 1999, Oncogene.

[24]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[25]  W. Leonard,et al.  Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity , 1998, The Journal of experimental medicine.

[26]  Michael P. Brown,et al.  Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.

[27]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[28]  L. Gordon,et al.  BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. , 1998, Blood.

[29]  Donald Metcalf,et al.  BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner , 1998, Oncogene.

[30]  A. Strasser,et al.  Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. , 1997, Journal of immunology.

[31]  R. Snell,et al.  Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Wilson,et al.  Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.

[33]  A. Strasser,et al.  The cell death inhibitor Bcl‐2 and its homologues influence control of cell cycle entry. , 1996, The EMBO journal.

[34]  L. Hennighausen,et al.  Time-Sensitive Reversal of Hyperplasia in Transgenic Mice Expressing SV40 T Antigen , 1996, Science.

[35]  G. Linette,et al.  Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Hoffman,et al.  Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines. , 1996, Blood.

[37]  J. Griffin,et al.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.

[38]  R. Hardy,et al.  Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. , 1996, Immunity.

[39]  F. Finkelman,et al.  bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice , 1996, The Journal of experimental medicine.

[40]  I. Sánchez-García,et al.  Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  al. et,et al.  Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice , 1995, Science.

[42]  C. Thompson,et al.  bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. , 1994, Development.

[43]  B. Groner,et al.  Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. , 1994, The EMBO journal.

[44]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[45]  J D Kemp,et al.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow , 1991, The Journal of experimental medicine.

[46]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[47]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[48]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[49]  R. R. Howe,et al.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. , 1982, The New England journal of medicine.

[50]  B. Göttgens,et al.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. , 2005, Blood.

[51]  R. V. van Etten.  Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. , 2004, Leukemia research.

[52]  Elizabeth Yang,et al.  BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. , 2002, Oncogene.

[53]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.

[54]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[55]  C. Thompson,et al.  Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). , 1996, The Journal of biological chemistry.

[56]  John Calvin Reed,et al.  BCL‐2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy , 1996, Journal of cellular biochemistry.

[57]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.